Mosanna Therapeutics is a technology company.
Mosanna Therapeutics has raised $80.0M across 1 funding round.
Mosanna Therapeutics has raised $80.0M in total across 1 funding round.
Mosanna Therapeutics has raised $80.0M in total across 1 funding round.
Mosanna Therapeutics's investors include EQT Life Sciences, Pivotal bioVenture Partners.
I need to clarify an important correction: Mosanna Therapeutics is not a technology company—it is a biotech/pharmaceutical company, not a technology firm. This distinction is fundamental to understanding what the company actually does.
Mosanna Therapeutics is a clinical-stage biotech company pioneering a pharmaceutical approach to treating obstructive sleep apnea (OSA).[2] Founded in 2022, the company has developed MOS118, a nasal spray designed to restore the body's natural airway control during sleep, offering a drug-based alternative to traditional mechanical treatments like CPAP machines.[2][3]
The company serves millions of OSA patients worldwide who currently rely on uncomfortable mechanical devices.[6] Mosanna's core problem-solving approach is fundamentally different from existing treatments: rather than mechanically forcing the airway open, the nasal spray reactivates upper airway muscles to help restore the body's natural breathing reflex during sleep.[4][6] The company has raised more than $80 million from prominent life sciences investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, and Norwest, with offices in Redwood City, California and Basel, Switzerland.[2]
Mosanna was founded in 2022 and is backed by a veteran leadership team with deep pharmaceutical and biotech experience.[3] The company's leadership includes executives with decades of combined experience: a Chief Regulatory Officer with over 40 years in pharmaceuticals and 30+ years in regulatory affairs; a Chief Financial Officer with 15 years of experience launching and scaling venture-backed startups; and a Chief Executive Officer with over 30 years in biotech who previously served as President and CEO of Otonomy, where he guided a successful IPO and achieved FDA approval for multiple therapies.[3]
The company emerged from recognition that current OSA treatments—primarily mechanical interventions—are often uncomfortable and disruptive to sleep quality, creating significant unmet patient needs despite affecting millions worldwide.[6]
Mosanna represents a shift in sleep apnea treatment philosophy—from external mechanical intervention to pharmaceutical activation of natural biological processes.[3][6] This approach aligns with broader trends in precision medicine and patient-centric drug development, where improving quality of life and treatment adherence are increasingly central to therapeutic success.
The timing is significant: OSA affects millions globally and is associated with serious comorbidities including heart disease and hypertension.[6] Current mechanical treatments have high non-compliance rates due to discomfort and sleep disruption, creating a substantial market opportunity for an effective pharmaceutical alternative. Mosanna's approach could influence how the broader biotech industry thinks about treating sleep disorders and other conditions currently managed through mechanical or device-based solutions.
Mosanna is advancing MOS118 through Phase 2 clinical development, with the next critical milestone being demonstration of efficacy and safety in larger patient populations.[4] The company's success will depend on clinical trial results proving that pharmaceutical activation of airway reflexes can match or exceed the efficacy of mechanical treatments while improving patient compliance and quality of life.
If successful, Mosanna could establish a new standard of care for OSA treatment and potentially open doors for similar pharmaceutical approaches to other conditions currently managed through mechanical intervention. The company's experienced leadership and substantial funding position it well to navigate the regulatory pathway, though biotech development timelines remain inherently uncertain. The broader question shaping their journey: can a pharmaceutical solution truly replace decades of mechanical treatment paradigms in sleep medicine?
Mosanna Therapeutics has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $80.0M Series A | EQT Life Sciences, Pivotal bioVenture Partners |